This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krajinovic, M. Articles by Sinnett, D. Search for Related Content PubMed PubMed Citation Articles by Krajinovic, M. Articles by Sinnett, D.

Genetic Polymorphisms of N-Acetyltransferases 1 and 2 and Gene-Gene Interaction in the Susceptibility to Childhood Acute Lymphoblastic Leukemia¹

Service d’Hématologie-Oncologie, Centre de Cancérologie Charles-Bruneau, Centre de Recherche, Hôpital Sainte-Justine (M. K., C. R., H. S., D. L., D. S.), and Département de Pédiatrie, Université de Montréal, Montreal, Quebec, H3T 1C5 Canada (D. L., D. S.).

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. In utero and postnatal exposures to various carcinogens may play a role in the etiology of this disease. N-acetyltransferases, encoded by the NAT1 and NAT2 genes are involved in the biotransformation of aromatic amines present in tobacco smoke, environment, and diet. Their rapid and slow acetylation activity alleles have been shown to modify the risk to a variety of solid tumors in adults. To investigate the role of NAT1 and NAT2 variants as risk-modifying factors in leukemogenesis, we conducted a case-control study on 176 ALL patients and 306 healthy controls of French-Canadian origin. Slow NAT2 acetylation genotype was found to be a significant risk determinant of ALL (odds ratio, 1.5; 95% confidence interval, 1.0–2.2) because of overrepresentation of the alleles NAT2*5C and *7B and underrepresentation of NAT2*4. Besides a slight increase in NAT1*4 allele frequency among cases, no independent association of NAT1 acetylation genotypes and ALL risk was observed. However, the risk associated with NAT2 slow acetylators was more apparent among homozygous individuals for NAT1*4 (odds ratio, 1.9; 95% confidence interval, 1.1–3.4). When NAT2 slow acetylators were considered together with the other risk-elevating genotypes, GSTM1 null and CYP1A1*2A, the risk of ALL increased further, which showed that the combination of these genotypes is more predictive of risk then either of them independently. These findings suggest that leukemogenesis in children is associated with carcinogen metabolism and consequently related to environmental exposures.

This article has been cited by other articles:

				V. L. Tyc, M. F. Hovell, and J. Winickoff Reducing Secondhand Smoke Exposure Among Children and Adolescents: Emerging Issues for Intervening with Medically At-Risk Youth J. Pediatr. Psychol., March 1, 2008; 33(2): 145 - 155. [Abstract] [Full Text] [PDF]

				M. Manuguerra, G. Matullo, F. Veglia, H. Autrup, A.M. Dunning, S. Garte, E. Gormally, C. Malaveille, S. Guarrera, S. Polidoro, et al. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions Carcinogenesis, February 1, 2007; 28(2): 414 - 422. [Abstract] [Full Text] [PDF]

				J. Healy, H. Belanger, P. Beaulieu, M. Lariviere, D. Labuda, and D. Sinnett Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia Blood, January 15, 2007; 109(2): 683 - 692. [Abstract] [Full Text] [PDF]

				P. Kum-Nji, L. Meloy, and H. G. Herrod Environmental Tobacco Smoke Exposure: Prevalence and Mechanisms of Causation of Infections in Children Pediatrics, May 1, 2006; 117(5): 1745 - 1754. [Abstract] [Full Text] [PDF]

				M. Krajinovic, S. Lamothe, D. Labuda, E. Lemieux-Blanchard, Y. Theoret, A. Moghrabi, and D. Sinnett Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia Blood, January 1, 2004; 103(1): 252 - 257. [Abstract] [Full Text] [PDF]

				G. M. Shaw, V. Nelson, D. M. Iovannisci, R. H. Finnell, and E. J. Lammer Maternal Occupational Chemical Exposures and Biotransformation Genotypes as Risk Factors for Selected Congenital Anomalies Am. J. Epidemiol., March 15, 2003; 157(6): 475 - 484. [Abstract] [Full Text] [PDF]

				M. Krajinovic, D. Labuda, G. Mathonnet, M. Labuda, A. Moghrabi, J. Champagne, and D. Sinnett Polymorphisms in Genes Encoding Drugs and Xenobiotic Metabolizing Enzymes, DNA Repair Enzymes, and Response to Treatment of Childhood Acute Lymphoblastic Leukemia Clin. Cancer Res., March 1, 2002; 8(3): 802 - 810. [Abstract] [Full Text] [PDF]